Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GLSI Greenwich LifeSciences Inc
- Stocks
- Healthcare
- NASDAQ: GLSI
Price (delayed)
$9.74
Market cap
$129.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$125.19M
Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a
Highlights
The quick ratio has plunged by 89% YoY and by 62% from the previous quarter
The net income has plunged by 78% YoY and by 50% from the previous quarter
Key stats
What are the main financial stats of GLSI
Market
Valuations
Earnings
Shares outstanding
13.27M
Market cap
$129.28M
Enterprise value
$125.19M
Price to earnings (P/E)
N/A
Price to book (P/B)
50.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.01M
Net income
-$15.79M
EBIT
-$15.79M
EBITDA
-$15.79M
Free cash flow
-$7.27M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
-$0.56
Book value per share
$0.19
Revenue per share
$0
TBVPS
$0.31
Total assets
$4.09M
Total liabilities
$1.56M
Debt
$0
Equity
$2.53M
Working capital
$2.53M
Debt to equity
0
Current ratio
2.62
Quick ratio
2.62
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-278.7%
Return on equity
-341.1%
Return on invested capital
N/A
Return on capital employed
-623.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GLSI stock price
How has the Greenwich LifeSciences stock price performed over time
Intraday
0.52%
1 week
3.29%
1 month
10.18%
1 year
-32.6%
YTD
-13.27%
QTD
2.1%
Financial performance
How have Greenwich LifeSciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.01M
Net income
-$15.79M
Gross margin
N/A
Net margin
N/A
The net income has plunged by 78% YoY and by 50% from the previous quarter
The operating income has dropped by 72% year-on-year and by 49% since the previous quarter
Price vs fundamentals
How does GLSI's price correlate with its fundamentals
Growth
What is Greenwich LifeSciences's growth rate over time
Valuation
What is Greenwich LifeSciences stock price valuation
P/E
N/A
P/B
50.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
GLSI's EPS has dropped by 75% year-on-year and by 51% since the previous quarter
GLSI's P/B is 141% higher than its 5-year quarterly average of 21.0 and 10% higher than its last 4 quarters average of 46.0
The equity has shrunk by 62% YoY and by 49% QoQ
Efficiency
How efficient is Greenwich LifeSciences business performance
The return on equity has dropped by 84% since the previous quarter
The ROA has shrunk by 70% QoQ
Dividends
What is GLSI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GLSI.
Financial health
How did Greenwich LifeSciences financials performed over time
GLSI's total assets is 162% greater than its total liabilities
The current ratio has plunged by 89% YoY and by 62% from the previous quarter
The quick ratio has plunged by 89% YoY and by 62% from the previous quarter
The company's debt is 100% lower than its equity
The equity has shrunk by 62% YoY and by 49% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.